Zai Lab Ltd.
Latest From Zai Lab Ltd.
MacroGenics' BLA for full approval in the US is under way and the company already has established a manufacturing facility in preparation for a launch.
Following Lilly’s decision to return rights to a BTK inhibitor it had licensed in from Hanmi, the South Korean pharma considers independently developing the molecule for other indications and vows to speed up development of other global drug programs.
The JVs will develop and commercialize therapeutics for multiple cancer types and autoimmune disorders in China. Novocure partners its Tumor Treating Fields technology with Zai Lab, while Fate and ONO will collaborate on off-the-shelf CAR-T therapies.
AstraZeneca/Merck & Co’s Lynparza has become the first PARP inhibitor to be approved in China, continuing a recent trend of accelerated reviews and approvals for novel therapies from multinationals in the country.
- Therapeutic Areas
- Immune Disorders
- Respiratory, Pulmonary
- ZAI Laboratory Inc.
- Parent & Subsidiaries
- Zai Lab Ltd.
- Senior Management
Samantha Du, PhD, Chmn. & CEO
Billy Cho, CFO
Jonathan Wang, VP, Head, Bus. Dev.
William Liang, Chief Commercial Officer
- Contact Info
Zai Lab Ltd.
Phone: 21 6163 2588
4560 Jinke Rd., Jinchuang Plaza Bldg. 1
Pudong, Shanghai, 201210
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.